media – Page 11 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Another biotech company is aiming for a Hong Kong IPO.

Fangtuo Bio, a company specializing in adeno-associated virus (AAV) vector gene therapy, officially submitted its A1 listing application to the main board of the Hong Kong Stock Exchange, becoming the first AAV gene therapy company to apply for listing in the Hong Kong stock market. UBS and Cathay Securities are acting as joint sponsors. 01 Differentiated pipeline layout Founded in 2019, Fangtuo Bio is a clinical-stage gene therapy company with an international footprint. It has built a product portfolio of eight self-developed drug candidates, primarily focusing on ophthalmic and cardiovascular disease areas with significant unmet clinical needs. Among them, two core products (FT-002 and FT-003) and one key product (FT-001) have entered the clinical stage , while the remaining five are in the preclinical and early-stage development stages. FT-002 , used to treat X-linked retinitis pigmentosa (XLRP), is the only therapy of its kind in China to have entered the ...
- Source: drugdu
- 45
- December 30, 2025
CMEF（tHIS ASEAN）

Organiser：Reed Sinopharm, APHM Time：July 28 – 30, 2026 Address：Kuala Lumpur City Centre, Kuala Lumpur, 50088, Malaysia Exhibition hall：Kuala Lumpur Convention Centre Product range: Medical Device Exhibition Area: Medical imaging, in-vitro diagnostics, operating rooms, medical electronic equipment, medical optics, medical robots, medical consumables, orthopedics, medical service disinfection and infection control, international smart health Pharmaceutical and Great Health Exhibition Area: Pharmaceuticals, Chinese herbal medicines, Chinese herbal decoction pieces/medicine-food homology products, traditional Chinese medicine health preservation, traditional Chinese medicine diagnosis and treatment and related equipment, pharmaceutical CRO/CMO/CDMO, personal care products, disinfection and protection products, adult products, medical beauty products, pharmaceutical logistics Rehabilitation and Elderly Care Exhibition Area: Brain science and brain-like research, robots, rehabilitation engineering and treatment equipment, rehabilitation physiotherapy equipment, spinal rehabilitation and health products, cardiopulmonary rehabilitation products, welfare aid products, home medical products and health management products, hearing assistance products, plantar pressure analysis and gait correction products, sleep aid products, ...
- Source: drugdu
- 63
- December 30, 2025
Brazil to launch single-dose dengue vaccination program; Chinese companies help boost vaccine production capacity

“The public is very concerned and eagerly anticipating the fact that dengue fever, an epidemic that has plagued impoverished communities for decades, can finally be ‘solved with a single injection’,” Valesca Mión, health inspector of the Guarulhostra Quelidad community vaccination site in São Paulo state, told reporters on the 26th. She added that she had been notified that, with increased production capacity, the vaccination program would be expanded to cover the entire population. Brazil’s Ministry of Health recently announced that Brazil will begin single-dose dengue fever vaccination by the end of January 2026, with the first batch of 300,000 doses of dengue vaccine developed by the Butantan Institute already delivered. The Brazilian government has initially allocated 368 million reais, planning to provide a total of 3.9 million doses to the public healthcare system. The Butantan Institute is expected to deliver another 1 million doses by the end of January 2026. ...
- Source: drugdu
- 75
- December 29, 2025
Sinovac Biotech’s adsorbent tetanus vaccine officially launched

On December 26, 2025, the first batch of adsorbed tetanus vaccine developed and produced by Beijing Sinovac Biotech Co., Ltd., a subsidiary of Sinovac Biotech, was shipped, officially entering the market. The vaccine, which received registration approval from the National Medical Products Administration in August 2025, represents the culmination of more than four years of research and development efforts, marking a new domestically produced option for tetanus active immunization in my country. Tetanus is an acute toxic disease caused by Clostridium tetani, which enters through breaks in the skin or mucous membranes. Globally, there are approximately one million cases annually, with 300,000 to 500,000 deaths. Without medical intervention, the mortality rate is nearly 100%, and even with standardized treatment, the global mortality rate remains between 30% and 50%. In my country, the overall level of tetanus protection among the adult population is insufficient. Traditional passive immunization agents have limitations such ...
- Source: drugdu
- 65
- December 29, 2025
A blockbuster drug with a market value of 5 billion yuan has been approved for a new indication

Recently, Shenyang Sansheng Pharmaceutical announced that its core product, recombinant human thrombopoietin injection (Tebio), has been officially approved by the National Medical Products Administration for a new indication: for adult patients with chronic liver disease-related thrombocytopenia (CLDT) who are scheduled to undergo surgery (including diagnostic procedures) . It is worth mentioning that, according to data from PharmNet, TEBIA’s sales in domestic public medical institutions exceeded 5 billion yuan in 2024. This new indication is its fourth approved indication, which will further consolidate its leading position in the thrombocytopenia treatment market. 01 The Road to Glory The story of TBIA began in the early days of China’s biopharmaceutical industry. In 2005, when imported biopharmaceuticals dominated the Chinese market, 3SBio’s independently developed recombinant human thrombopoietin injection was approved for marketing, becoming the world’s only commercially available recombinant human thrombopoietin product and China’s first Class 1 new drug biological product approved in China. ...
- Source: drugdu
- 66
- December 29, 2025
2025 Biopharmaceutical CEO Star

In the biopharmaceutical industry in 2025, the names of several key figures were frequently mentioned. The choices they made during merger and acquisition negotiations, pipeline advancement, commercialization, or company turning points directly influenced the company’s trajectory that year. 01 CEOs who drive up the value of M&A deals In the unpredictable biopharmaceutical M&A landscape of 2025, one of the most memorable cases is the “value maximization” case involving Metsera . The obesity market was already hot due to GLP-1 competition, but Metera wasn’t a giant company. Its value stemmed more from the potential assessment of its early assets and its judgment of the future market landscape. The co-founders, Whit Bernard and Clive Meanwell , seized the opportunities presented by the times. Amidst a dazzling array of offers, they skillfully used their business negotiation techniques, controlling the pace, information disclosure, and bidding mechanisms to ultimately push Pfizer’s seemingly settled $7 billion ...
- Source: drugdu
- 51
- December 29, 2025
Hybio Pharmaceutical and Dr. Reddy’s Forge Strategic Cooperation on Peptide APIs to Advance Global Peptide Layout

Journalists have learned from Hybio Pharmaceutical (300199) that on December 25, a signing ceremony was held in Beijing between Hybio Pharmaceutical and the world-renowned pharmaceutical company Dr. Reddy’s Laboratories. The two parties formally signed a non-binding term sheet for strategic cooperation in the field of peptide Active Pharmaceutical Ingredients (APIs) and related formulations, marking a successful start to their strategic partnership. It is reported that this cooperation resulted from in-depth prior consultations and strategic alignment. In September 2025, the global CEO of Dr. Reddy’s led a team to visit Hybio’s headquarters and production bases. The two sides held deep discussions on key issues such as peptide drug R&D innovation, global commercialization strategies, and potential strategic directions, followed by multiple rounds of face-to-face exchanges during international conferences such as CPHI. According to the cooperation framework, the two parties have reached a preliminary consensus on the scope of cooperation and overall strategy ...
- Source: drugdu
- 56
- December 29, 2025
Phase II Clinical Trial Application for New Lung Cancer Intraoperative Visualization Drug FZ-P001 Sodium for Injection Has Been Accepted

China Securities Intelligent Finance News — On the evening of December 28, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (01349) announced that it has received an “Acceptance Notice” from the National Medical Products Administration (NMPA). The Phase II clinical trial application for its self-developed Class 1 innovative drug, FZ-P001 Sodium for Injection, has been accepted. The drug is intended for the intraoperative visualization of malignant lesions in patients with known or suspected lung cancer. According to the announcement, the drug is an innovative photosensitizer targeting folate receptor alpha (FRα). It utilizes near-infrared (NIR) fluorescence imaging technology to indicate residual tumor tissue and surgical margins during procedures, aiming to improve the surgical resection outcomes for solid tumors such as lung cancer. Citing relevant data, the announcement noted that in 2022, China saw 1.061 million new lung cancer cases and 733,000 deaths, with lung cancer ranking first in both incidence and mortality among malignant tumors. The ...
- Source: drugdu
- 47
- December 29, 2025
【EXPERT Q&A】What are the main testing standards for medical devices?

Drugdu.com expert’s response: The medical device testing standard system is extensive and meticulous, covering multiple dimensions such as physical properties, chemical properties, biocompatibility, electrical safety, environmental adaptability, software functionality, sterilization validation, and service life assessment. Below are some core aspects: I. Physical Property Testing Standards Testing Items: Dimensional accuracy, surface roughness, material hardness, pressure resistance, tensile strength, sealing performance, wear resistance, fatigue life, motion accuracy, positioning accuracy, etc. Relevant Standards: GB/T 16886.1, GB 9706.1, YY/T 0287, GB/T 14710, etc. II. Chemical Property Testing Standards Testing Items: Material composition, chemical stability, leachables/extractables, residual solvents, additive content, heavy metal content, etc. Relevant Standards: Specific standards involving material composition analysis, impurity and additive testing, migration testing, etc. III. Biocompatibility Testing Standards Testing Items: Cytotoxicity tests, skin sensitization tests, intracutaneous reactivity tests, acute systemic toxicity tests, blood compatibility tests, implantation tests, genotoxicity tests, subchronic toxicity tests, etc. Relevant Standards: ISO 10993 series standards (e.g., ...
- Source: drugdu
- 67
- December 29, 2025
Innovative Drug KarXT® (Karigel®) Approved in China

On December 23, Zai Lab officially announced that the National Medical Products Administration (NMPA) of China has approved the New Drug Application (NDA) for Xanomeline-Trospium Chloride Capsules (Brand name: KarXT®/Kaigele®), indicated for the treatment of adult patients with schizophrenia. The press release noted that this marks the first approved schizophrenia therapy with a novel mechanism of action in more than 70 years. Unlike traditional antipsychotics that target dopamine receptors, KarXT® exerts its effects on core disease pathways by selectively acting on muscarinic acetylcholine M1 and M4 receptors in the brain. Schizophrenia affects over 8 million adults in China, yet fewer than half of them receive formal treatment. The disease severely impairs patients’ abilities to think, feel, and behave, characterized by positive symptoms, negative symptoms, and cognitive impairments. Unfortunately, many patients continue to face inadequate symptom relief or adverse effects during treatment with existing antipsychotic medications. Statistics show that approximately 75% ...
- Source: drugdu
- 94
- December 26, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.